Search research articles
Contact Us
Filters
Showing results (181-190 of 199) with videos related to
Page
of 20
Sort By:
AIDS (London, England)
|
October 18, 2022
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
Catharine Chambers, Hasina Samji, Curtis L Cooper, et al.
AIDS (London, England)
|
January 5, 2026
SARS-CoV-2 breakthrough infection among people with and without HIV in Ontario, Canada
Cassandra Freitas, Curtis L Cooper, Abigail E Kroch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 13, 2019
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs
Sarah M Zaidan, Louise Leyre, Rémi Bunet, et al.
HIV Medicine
|
October 2, 2023
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV
Katia Giguère, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
AIDS (London, England)
|
October 18, 2024
Coronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves
Catharine Chambers, Curtis L Cooper, Abigail E Kroch, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The New England Journal of Medicine
|
March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Vaccines
|
May 25, 2024
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study
Cecilia T Costiniuk, Terry Lee, Joel Singer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 9, 2016
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons
Laurence Brunet, Erica E M Moodie, Jim Young, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 199) with videos related to
Sort By:
Page
of 20
AIDS (London, England)
|
October 18, 2022
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV
Catharine Chambers, Hasina Samji, Curtis L Cooper, et al.
AIDS (London, England)
|
January 5, 2026
SARS-CoV-2 breakthrough infection among people with and without HIV in Ontario, Canada
Cassandra Freitas, Curtis L Cooper, Abigail E Kroch, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 13, 2019
Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs
Sarah M Zaidan, Louise Leyre, Rémi Bunet, et al.
HIV Medicine
|
October 2, 2023
Baseline characteristics of a prospective cohort study of aging and cardiovascular diseases among people living with HIV
Katia Giguère, Carl Chartrand-Lefebvre, Jean-Guy Baril, et al.
AIDS (London, England)
|
October 18, 2024
Coronavirus disease 2019 outcomes in a population-based cohort of people with HIV and a matched cohort of people without HIV during Omicron variant waves
Catharine Chambers, Curtis L Cooper, Abigail E Kroch, et al.
The Lancet. HIV
|
August 11, 2023
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, et al.
The New England Journal of Medicine
|
March 5, 2020
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe Orkin, Keikawus Arasteh, Miguel Górgolas Hernández-Mora, et al.
Vaccines
|
May 25, 2024
Correlates of Breakthrough SARS-CoV-2 Infections in People with HIV: Results from the CIHR CTN 328 Study
Cecilia T Costiniuk, Terry Lee, Joel Singer, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
January 9, 2016
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
Sahar Saeed, Erin C Strumpf, Sharon L Walmsley, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 25, 2015
Progression of Liver Fibrosis and Modern Combination Antiretroviral Therapy Regimens in HIV-Hepatitis C-Coinfected Persons
Laurence Brunet, Erica E M Moodie, Jim Young, et al.
Page
of 20